Abeona Therapeutics (ABEO) Projected to Post Earnings on Monday

Key Points

• Abeona Therapeutics (NASDAQ:ABEO) is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.39) per share and revenue of $21.71 million for the quarter.
• The company's stock currently holds a market cap of $331.45 million and a PE ratio of -5.09, with shares trading around $6.48.
• Insider transactions reveal a significant decrease in holdings by executives, with the total insider sales in the last ninety days amounting to $1.48 million.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Abeona Therapeutics to post earnings of ($0.39) per share and revenue of $21.71 million for the quarter.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.11. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Abeona Therapeutics Stock Performance

Shares of NASDAQ:ABEO traded down $0.01 during trading on Monday, reaching $6.48. 47,291 shares of the stock were exchanged, compared to its average volume of 1,043,578. The company has a current ratio of 4.90, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The firm has a market cap of $331.45 million, a PE ratio of -5.09 and a beta of 1.54. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.32. The stock has a 50-day moving average price of $6.19 and a 200-day moving average price of $5.66.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on ABEO shares. Stifel Nicolaus decreased their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $19.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, July 14th. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $19.25.

Insider Transactions at Abeona Therapeutics

In related news, Director Faith L. Charles sold 10,738 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $62,924.68. Following the transaction, the director owned 139,094 shares in the company, valued at $815,090.84. The trade was a 7.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brendan M. O'malley sold 17,428 shares of the company's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $102,128.08. Following the transaction, the senior vice president owned 360,817 shares in the company, valued at $2,114,387.62. This represents a 4.61% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 239,626 shares of company stock worth $1,476,027. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Abeona Therapeutics

A hedge fund recently raised its stake in Abeona Therapeutics stock. Goldman Sachs Group Inc. boosted its position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 49.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 200,450 shares of the biopharmaceutical company's stock after buying an additional 66,422 shares during the quarter. Goldman Sachs Group Inc. owned 0.41% of Abeona Therapeutics worth $954,000 as of its most recent filing with the Securities & Exchange Commission. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.